Shandong Eye Institute   Report issue

Academic/Hospital Phase 2
Founded: Qingdao China (1991)

Organization Overview

First Clinical Trial
2019
NCT04092907
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

QINGDAO EYE HOSPITAL

Active Ingredients

Drugs in Phase 2 Trials (1)

tanfanercept (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1